Cytovia and Cellectis Expand Their TALEN® Gene-Edited iNK Partnership to Enable Broader Collaboration in China

Cytovia Therapeutics, Inc. and Cellectis announced that they have expanded their collaboration of TALEN® gene-edited iPSC-derived natural killer (NK) and chimeric antigen receptor (CAR)-NK cells to include new CAR target and development in China by Cytovia’s joint venture entity, CytoLynx Therapeutics.